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Abstract- Alzheimer’s disease (AD) is a uniquely human disorder. Although the pathogenesis of AD 
is not fully understood, growing evidence indicates that the deposition of beta-amyloid (Aβ) and the 
local reactions of various cell types to this protein play major roles in the development of the disease. In 
the present study transgenic mice expressing mutant amyloid precursor protein (APP) has been used. 
These mice exhibit selective neuronal death in the brain regions that are most affected in AD, 
suggesting that amyloid plaque formation is directly involved in AD neurons loss. Brains from 12 
transgenic animals and 12 age-matched non transgenic littermate controls (1 and 2 years old) were 
examined histopathologically. One year old transgenic animals (n=6) exhibit deposits of human Aβ in 
the hippocampus, corpus callosum and cerebral cortex. By 2 years of age, a great number of diffuse and 
mature plaques were present in the cortex and hippocampus, and subcortical regions like thalamus and 
striatum. Another major finding was reduction of cholinergic cells in the medial septum, striatum and 
diagonal band of Broca. The present data are consistent with the hypothesis that the neuropathology 
begins in the cerebral cortex and hippocampus before spreading in a retrograde fashion to subcortical 
regions. 
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INTRODUCTION 
 
Alzheimer’s disease (AD) is a progressive 
neurodegenerative disorder that affects a large 
proportion of elderly people. Although genetic 
factors seem to strongly contribute to disease 
susceptibility, only a small number of cases are 
caused by dominant mutations (1). To date, all such 
mutations alter processing of the amyloid precursor 
protein (APP), leading to changes in the production 
or fibrillization of amyloid-β (Aβ), the major 
constituent of amyloid plaques in AD brain (1-3). 
Aβ peptide, derived from the APP, seems to have 
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a central role in the neuropathology of AD (4, 5), 
which is characterized by formation of senile 
plaques and neurofibrillary tangles, and loss of 
neurons (4, 5). Amyloid peptide plaques, one of the 
two diagnostic brain lesions observed in Alzheimer’s 
original patient, are microscopic foci of extracellular 
amyloid deposition. These plaques and associated 
axonal and dendritic injury generally can be found in 
large numbers in the limbic and association cortices 
(3). Such plaques contain extracellular deposits of 
Aβ that occur principally in a filamentous form, as 
star-shaped masses of amyloid fibrils. Dystrophic 
neuritis occurs both within this amyloid deposit and 
immediately surrounding it. 
The pathology of AD involves production and 
deposition of Aβ in senile plaques in an insoluble 
form (amyloid). The amyloid deposits could be 
directly toxic to cells or neurodegeneration could 
involve amyloid-related activation of glia and 
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associated inflammatory responses (6). Evidence that 
Aβ immunization also reduces cognitive dysfunction 
in murine models of AD would support the 
hypothesis that abnormal Aβ processing is essential 
to the pathogenesis of AD, and would encourage the 
development of other strategies directed at the 
amyloid cascade (7).  
Besides the extracellular deposition of Aβ, the AD 
brain is characterized by intracellular neurofibrillary 
tangles and profound changes in the cholinergic 
system (8, 9). The major cholinergic innervation to 
the cerebral cortex originates from the nucleus 
basalis of Meynert (NBM), together with the 
horizontal limb of the diagonal band of Broca 
(HDBB). Cholinergic innervation to hippocampus is 
mainly provided by the medial septum (MS) and the 
vertical limb of the diagonal band of Broca (VDBB) 
(10, 11). In AD brain, a profound loss of these 
cholinergic basal forebrain neurons has been 
reported (12, 13). In both neocortex and 
hippocampus of AD brain, a loss of cholinergic 
fibers and terminals, decrease in cholinergic 
receptors and/or signal transduction and significant 
reductions in choline acetyltransferase (ChAT) and 
acetylcholinesterase (AChE) enzyme activities have 
been reported (12-18).  
The relationship between cerebral amyloid 
deposition and cholinergic depletion in AD remains 
poorly understood (4, 19, 11). This neuron loss may 
be the result of Aβ neurotoxicity to the cholinergic 
terminals followed by retrograde degeneration. 
Alternatively, degeneration of cholinergic basal 
forebrain neurons may be the primary lesion with 
subsequent loss of cortical cholinergic innervation. It 
has also been reported that AChE accelerates the 
assembly of Aβ into insoluble amyloid fibrils (20, 
5). Accordingly, dysfunction of the cholinergic 
system may influence cerebral amyloidosis. Vice 
versa, it has been demonstrated that Aβ is neurotoxic 
to cholinergic neurons and that low concentrations of 
Aβ can directly inhibit cholinergic signaling (21, 
22). Thus, increased Aβ levels may contribute 
physiologically and/or pathologically to the 
cholinergic changes in AD brain.  
Several transgenic mice models over expressing 
APP and its clinical mutants have been generated 
which recapitulate aspects of AD. A transgenic 
mouse model of AD has been developed that 
expresses high levels of human mutant APP (23, 24). 
The transgenic animals were generated using a 
platelet-derived growth factor-β promoter driving a 
human APP (h APP) minigene encoding the APP717 
V6F mutation associated with familial AD (25). 
Between 6-9 months of age heterozygous PDAPP 
mice exhibit thioflavin-S-positive Aβ deposits, 
neurotic plaques, synapse loss, astrocytosis and 
microgliosis in the cortex and hippocampus. The 
magnitude of the cortical neuropathology increases 
after 9 months of age. The Aβ-containing plaques 
are directly associated with reactive gliosis and 
dystrophic neuritis, suggesting that the plaques may 
induce neurodegenerative changes in animals over 9-
months of age; however, there is no evidence of 
neurofibrillary tangles or widespread neuronal loss. 
Many neurons in the brain regions typically affected 
in AD, including entorhinal cortex, hippocampus, 
parahippocampal gyrus, amygdala, frontal, temporal, 
parietal and occipital association cortices, and 
certain subcortical nuclei projecting to these regions, 
contain large, non membrane bound bundles of 
abnormal fibers that occupy much of the perinuclear 
cytoplasm (26). The most notable feature of these 
transgenic mice is their Alzheimer like 
neuropathology, which includes extracellular Aβ 
deposition, dystrophic neuritic component, gliosis 
and loss of synaptic density with regional specificity 
resembling that of AD. Based on the limited 
sampling to date, plaque density appears to increase 
with age in these transgenic mice, as it does in 
humans (26). In AD, there is degeneration of cortical 
neurons (27) and of subcortical neurons that project 
to the cortex (28). Several studies have found 
evidence of cholinergic nerve terminal abnormalities 
in AD mouse models (4, 6, 29-31) but they have not 
found clear evidence of cholinergic cell 
degeneration.  
In the present experiment we have studied these 
mouse models to evaluate cholinergic alternations 
that result from, or lead to, cerebral amyloidosis. For 
this purpose we have used biochemical and 
morphological techniques to assess cholinergic 
changes in neocortex and basal forebrain of PDAPP 
transgenic mice and moreover, to test the hypothesis 
that cortical cholinergic depletion has an effect on 
amyloid plaque formation. 
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MATERIALS AND METHODS 
 
Transgenic mice 
 
Games et al. have produced a transgenic mouse 
model of AD that expresses high level of human 
mutant APP with valine at residue 717 substituted by 
phenylalanine (23). Homozygous mice were derived 
over 8-10 generations from hybrid backgrounds 
representing combinations of C57BL/6 + DBA + 
Swiss Webster strains. A total of 12 homozygous 
animals were compared with 12 wild-type mice from 
the same hybrid strain at 1-year and 2-years of age. 
All experiments on animals were performed in 
accordance with UK legal requirements. 
 
Histology and immunohistochemistry 
 
Male mice were deeply anesthetized with 
Nembutal (120 mg/kg, i.p.) and perfused with saline 
followed by 10% neutral buffered formalin. Forty 
µm thick coronal sections were cut on a freezing 
microtome. For immunocytochemical staining the 
following antibodies were used: 1) human-specific 
monoclonal Aβ antibodies which identifies human 
Aβ in transgenic mice (antibody 3D6, Elan 
pharmaceutical, Inc); and 2) polyclonal goat 
antibody against human ChAT (AB144P; Chemicon 
International, Inc.).  
The sections were processed for 
immunocytochemistry using the ABC method with 
free-floating sections. In brief, sections were washed 
in phosphate buffered saline (PBS), treated with 1% 
hydrogen peroxide in PBS, and blocked in 5% 
normal goat serum or normal horse serum in 0.3% 
Triton X-100 in PBS (PBST). On day 1, sections 
were incubated with diluted primary antibodies (1: 
1,000 anti-Aβ, and 1:200 anti-ChAT) with 1% normal 
serum in PBST, overnight at room temperature. On 
day 2, the sections were incubated with secondary 
antibodies (1.5 µg/ml either biotinylated goat anti-
rabbit IgG, or horse anti-mouse IgG, Vector Labs, 
Burlingame, CA) for 30 minutes, and with an 
avidion/biotin/peroxidase reagent (1: 250 dilution; 
ABC Elite, Vector Labs) for 1 hour. Sections were 
reacted   in   an   acetate  buffer  (pH 6.0)  containing 
0.035% diaminobenzidine tetrahydrochloride, 2.5% 
nickel ammonium sulfate, and 0.001% hydrogen 
peroxide for 5-10 minutes.  
All incubations were done on a shaker table, at 
room temperature and with 3×10 minute washes in 
PBS. Sections were mounted on subbed slides, 
dehydrated, and cover slipped. To be certain of the 
specificity of the immunoreactivity, the primary 
antibody step was omitted in the staining procedure. 
This procedure blocked specific immunostaining 
with both antibodies. The immunohistochemical 
staining procedure was run on tissue sections from 
both transgenic and wild-type controls at the same 
time in order to control for antibody concentration, 
reaction times, etc., since these variables influence 
staining intensity. 
 
Morphometry 
 
To count the basal forebrain cholinergic cell 
profiles, Neurolucida software was used 
(MicroBrightField, Inc.) with a × 40 microscope 
objective. Outlines were drawn at low power (2.5 ×) 
around the striatum, the MS nucleus, VDDB and 
HDBB. Cell profiles that measured > 10 µm in 
diameter were not counted within the confines of 
each of the four nuclei. Evenly spaced sections were 
counted for a total of 9-11 sections/brain, and more 
sections were generally present in the control mice 
vs. PDAPP mice throughout the rostral-caudal extent 
of each nucleus. Cell profile counting began rostrally 
at the origin of the VDBB, and stopped at the level 
of the decussation of anterior commissure. The long 
axis of cholinergic somata was measured at 400 × 
magnification in 30-60 cells in each brain. The total 
number of cell profiles within each of the cholinergic 
nuclei was estimated using Abercrombie’s correction 
factor for split cell counting error (Abercrombie, 
1946). The person performing the counts was blind 
to the animal’s experimental condition. 
 
Statistical analysis 
 
For the statistical analysis, we used Chi square 
and Fisher’s exact tests and P values were  computed 
by SPSS software, version 11. P value < 0.05 was 
considered as significant. 
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RESULTS 
 
Amyloid peptide plaques were found in large 
numbers in the limbic and association cortices in 
sections stained with antibody against human Aβ. 
We also found that Aβ-containing neuritic plaques 
accumulate with age in the PDAPP mouse (Fig. 1). 
By 12-months of age, diffuse and mature plaques 
were present in the cortex and hippocampus but no 
plaque in subcortical regions such as the thalamus or 
striatum was found (Fig. 1. A). Compared to the 1-
year old mouse, at 2 years of age there were many 
more mature and diffuse plaques in the cerebral 
cortex and hippocampus (Fig. 1. B). A lower number 
of compacted plaques were also found in subcortical 
regions such as the caudate-putamen (CPU) and in 
white matter regions.  
To view cholinergic changes as well, tissues were 
stained for both ChAT (black reaction) and Aβ 
(brown reaction). Cholinergic disruption in 
neocortex of aged PDAPP mice was most evident 
around plaques. As shown in figures 1. C and D, 
immunostaining for Aβ revealed numerous compact 
amyloid plaques and diffuse amyloid (arrow heads) 
in neocortex of 12 and 24-month old PDAPP mice. 
Fibers frequently grew toward the amyloid but then   
formed loops or sharply turned around to grow away 
from the amyloid. 
The basal forebrain cholinergic neurons that 
project to cortical and hippocampal regions reside in 
the MS nucleus, and in the VDBB and HDBB and 
CPU. Figure 2 (A, B and C) illustrates sections 
within the basal forebrain complex 
(MS/VDBB/HDBB) and CPU. Representative 
sections immunostained with an antibody against 
choline acetyltransferase. There was a reduction in 
the number of basal forebrain cholinergic neurons in 
the 2-year old PDAPP mice. Cell profile counts were 
taken from sections in control and PDAPP mice in 
the combined MS and VDBB, and from the HDBB 
and CPU. In the PDAPP vs. control mice there were 
17% fewer neurons in the HDBB (Student’s t = 2.31, 
P = 0.038), and 14% fewer neurons in the MS + 
VDBB and CPU (Student’s t = 2.89, P = 0.016). In 
the four regions combined, there were 15% fewer 
neurons in the PDAPP vs. control mice (Student’s t 
= 2.83, P = 0.018). Cell size in the HDBB and MS + 
VDBB and CPU, as measured by the long-axis of 
the somata, was not significantly different in the two 
groups. ANOVA for ChAT-positive neuron number 
were calculated for the MS/VDBB/HDBB and CPU 
separately in the PDAPP and control mice (Fig. 2. D).  
            
        
           
          A                                                  B                                                C                                                 D 
 
Fig. 1. Amyloid-β (Aβ) containing plaques accumulate with age in the transgenic mice over expressing mutant human amyloid 
precursor protein (PDAPP). Brain sections were stained with an antibody against human Aβ. There are very few Aβ-containing 
plaques in the 1-year old PDAPP mouse (A). At 2 years of age, there are many mature and diffuse plaques in the cerebral cortex, 
hippocampus and caudate-putamen and in white matter regions (B). Mature neuritic plaques in a 2-year-old mouse are covered with 
markedly swollen ChAT containing varicosities (arrow, C). Neuritic plaques in 1-year-old PDAPP mouse, a diffuse plaque (arrow) 
can be seen surrounded by numerous cholinergic fibers with nerve terminal varicosities (D). The plaque is located in the 
hippocampus. Section stained only for ChAT. CPu, caudate-putamen, df, dorsal fornix; DE, dentated gyrus; Th, thalamus. Scale bar, 
300 µm in A and B and 15 µm in C and D. 
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Fig. 2. There is age related change in the number of basal forebrain cholinergic neurons in the PDAPP mouse. Basal forebrain 
cholinergic neurons were examined in the medial septal (MS) nucleus and in the vertical limb of the diagonal band of Broca (VDBB) 
and horizontal limb of the diagonal band of Broca (HDBB) (A, B) and in caudate-putamen (CPU) (C). The sections are 
immunostained with an antibody against choline acetyltransferase; scale bar, 300 µm. Fig. 2. D shows comparison of cell counts 
taken from sections in control and PDAPP mice in the combined MS and VDBB and CPU in the 1-year (young) and 2-year old 
PDAPP mice (aged) vs. age-matched controls. Data represent total profile counts for individual animals in the four groups, and 
represent the estimated total number of cells after correction for split cell count error. Lines represent the mean values for the group 
and indicate that the difference was statistically significant vs. control animals at 2-years of age (P< 0.01). In PDAPP vs. control 
mice, there was a difference of around 15% in the number of somata in MS + VDBB + CPU. 
 
DISCUSSION 
 
The demonstration that Aβ and APP C-terminal 
fragments containing Aβ are neurotoxic in cell 
culture gave rise to the hypothesis that Aβ may be a 
primary cause of neuronal degeneration in AD (32, 
33). The neurotoxicity of Aβ is dependent on its 
aggregated state (33, 31, 34). The cholinergic 
pathology in the PDAPP mouse is similar to that in 
AD post-mortem brain where there are marked 
decreases in the density of cholinergic nerve 
terminals and ChAT enzyme activity (11), and the 
cholinergic deficits are positively correlated with the 
level of cognitive impairment in AD patients (14). 
Deposition of amyloid is a hallmark lesion of 
AD, and genetic analysis has demonstrated that Aβ 
is central to AD pathogenesis (35, 36). Similarly, 
depletion of the cholinergic system is a robust 
finding in AD and correlates with cognitive 
impairment (9, 37, 26). Yet, the link between 
cerebral amyloidosis and the cholinergic deficit 
remains poorly understood. The present study was 
undertaken to investigate alternations in the 
cholinergic system in the PDAPP mouse model of 
Alzheimer’s disease. The mice develop amyloid 
plaques and cerebrovascular amyloid deposition 
throughout the neocortex and hippocampus, with 
only modest amyloid deposition in the basal 
forebrain (38, 39). Individual amyloid deposits in 
PDAPP mice are also morphologically similar to 
those in AD brain and include congophilic amyloid 
cores, amyloid associated dystrophic neuritis, 
astrocytosis, and micro gliosis (40). 
Results of the present study reveal a robust 
decrease in cholinergic fiber length with distorted 
and dystrophic cholinergic fibers surrounding the 
amyloid, very similar to that in AD brain (11). Our 
results suggest that the cortical cholinergic deficit in 
PDAPP mice is locally induced by Aβ deposition. 
These results are also consistent with earlier 
observations that retrograde degeneration in the 
NBM only occurs after more severe cortical tissue 
damage (41). 
Correlative analysis of ChAT and AChE enzyme 
activities and amyloid load in AD brain has revealed 
conflicting findings. Some studies have found 
negative correlations (9, 42, 43, 44) whereas others 
have found no relation (11, 45, 46). In AD and in 
mice, a significant amount of ChAT and AChE 
staining is associated with dystrophic neuritis 
surrounding amyloid plaques (47, 31). The present 
data indicate that the cholinergic nerve terminal 
degeneration occur around the plaques and can 
precede Aβ plaque deposition. Behavioral 
impairments (48), synaptic transmission deficits 
(49), and loss of cortical nerve terminal markers (50) 
precede the formation of neuritic plaques in mouse 
models of AD.  
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At 2-year of age, there is a very high density of 
Aβ containing neuritic plaques in the cortex but only 
low density in the striatum of the homozygous 
PDAPP mice. At the same point of time there is a 
reduction in cholinergic nerve terminals around the 
plaque at cortex and reduction in ChAT enzyme-
activity in striatum. In this study, the density of 
cholinergic nerve terminals in the cortex was 
reduced by over 60% in the 2-year old PDAPP 
mouse, and the reduction in the number of basal 
forebrain cholinergic somata that innervate this 
cortical region was only 15%. Cholinergic cell 
degeneration appears to be due to a retrograde 
mechanism in AD as well. It has been hypothesized 
that cholinergic depletion in AD contributes to 
cerebral amyloidosis. This hypothesis is based on the 
observation that protein kinase C through muscarinic 
receptor binding stimulates the non amyloidgenic 
pathway of APP processing by increasing soluble 
APP production and reducing Aβ generation (51-53). 
Thus the loss of the cholinergic innervation may lead 
to increased production of Aβ and amyloid 
deposition. In vivo support for altered APP processing 
has been provided in both NBM-lesioned rats and in 
rats after muscarinic agonist treatment (1, 54). 
In conclusion, our results suggest that the 
homozygous PDAPP mouse exhibits cholinergic 
degenerative pathology similar to that observed in 
AD, and it has been speculated that AD 
neuropathology begins in the cerebral cortex and 
spreads to subcortical nuclei via the axonal 
projections to the cortex. The subcortical cell 
degeneration has been proposed to occur via 
retrograde transport of a toxin, such as Aβ. 
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